# Hepatorenal Syndrome (HRS) (ICD–10 N19, K76.7, N18.9)
— Patient meets diagnostic criteria:
— (1) Advanced liver disease w/ portal hypertension, (2) AKI w/o other clear explanation (e.g., shock, nephrotoxic agents), (3) Bland sediment on UA: urine RBCs <50/hpf, urine protein <500 mg/day
— (4) No improvement in renal function after 48 hrs of diuretic cessation and volume expansion w/ albumin (1g/kg/day up to 100g/day)
— Pathophysiology:
— Increased splanchnic/systemic vasodilation (e.g., due to nitric oxide)
— Decreased renal perfusion pressure w/ compensatory renal vasoconstriction
— Marked reduction in GFR and urine output
— Precipitating factors: Infection (e.g., SBP), GI hemorrhage, Rapid progression of liver failure
— Clinical presentation: Oliguria (<400mL in 24hrs), progressive decline in renal function, FENa <1%
— Potential complications:
— Progression to type 1 HRS (rapid onset w/ poor prognosis)
— Worsening ascites, encephalopathy, or coagulopathy
— Increased mortality w/o liver transplant
— Red–flag findings:
– Rapidly rising sCr or reduced UOP
– Severe hypoalbuminemia or refractory hypotension
— Reassuring findings: stable sCr, improved UOP, response to volume expansion
PLAN
1. Diagnostics
— Labs: BMP, CBC, INR/PTT, LFTs, serum ammonia, UA, urine osmolality, uNa, spot urine protein:creatinine ratio
— Imaging: Renal US to exclude obstruction or intrinsic renal disease
— Paracentesis (if ascites present): cell count, culture, albumin (SAAG)
2. Volume expansion
— Albumin infusion: 1g/kg/day (max 100g/day) for 2 days
— Repeat sCr after albumin administration
3. Vasoconstrictor therapy
— Midodrine 7.5–15 mg PO TID + Octreotide SC 100–200 mcg TID
— ICU patients: Norepinephrine IV infusion titrated to MAP >65 mmHg as an alternative or adjunct
— Terlipressin (if available): 1 mg IV Q4–6H, titrated based on response
4. Diuretic cessation
— Hold loop diuretics to allow renal recovery
5. Infection management
— Empiric ABx for SBP: Cefotaxime 2g IV Q8H
— Continue ABx until culture results or a minimum of 5 days
6. Definitive therapy
— Liver transplant: Best long–term treatment; initiate referral and MELD optimization
— TIPS: Considered for patients unresponsive to medical therapy, with caution due to high MELD and procedural risks
7. Renal replacement therapy (RRT)
— Indicated for severe AKI unresponsive to medical management
— CRRT preferred for hemodynamically unstable patients
8. Supportive care
— Nutritional support: low–sodium diet (<2g/day), fluid restriction (1–1.5L/day if hyponatremia)
— Avoid nephrotoxins (e.g., NSAIDs, aminoglycosides)
9. Monitoring
— sCr, UOP, electrolytes (Mg, K, phos) Q12–24H based on clinical stability
— MAP targets and signs of ischemia if vasoconstrictors used
10. Considerations for alternative therapies
— TIPS or experimental therapies if standard medical treatment fails
LIVER DISEASE – FUNDAMENTALS – OVERVIEW AND TREATMENT
DIFFERENTIAL DIAGNOSIS
1. Alcoholic hepatitis: Consider in patients with recent heavy alcohol intake, jaundice, tender hepatomegaly, and elevated liver enzymes (AST:ALT ratio >2), often with fever and leukocytosis
2. Alcoholic cirrhosis: Consider in patients with chronic alcohol use, signs of portal hypertension (e.g., ascites, varices), and liver dysfunction; confirmed with imaging or biopsy showing nodular liver architecture
3. Alcoholic fatty liver disease: Consider in patients with a history of alcohol use, mild elevations in liver enzymes, and imaging showing hepatic steatosis without signs of inflammation or fibrosis
4,5,6,7. Viral hepatitis (A, B, C): Consider if risk factors such as IV drug use or sexual transmission are present; look for positive viral serologies
8. Non-alcoholic fatty liver disease (NAFLD): Consider in patients with metabolic syndrome, obesity, or diabetes; usually AST:ALT ratio <1
9. Autoimmune hepatitis: Consider in patients with positive autoimmune markers (ANA, ASMA, LKM1), elevated IgG levels, and in absence of significant alcohol intake
10. Hemochromatosis: Suspect in patients with family history, elevated ferritin and transferrin saturation; confirm with genetic testing
11. Wilson’s disease: Consider in younger patients (<40 years) with neuropsychiatric symptoms, low ceruloplasmin, and elevated urinary copper
12. Drug-induced liver injury (DILI): Consider if there’s a history of recent drug intake, especially acetaminophen, statins, or herbal supplements
13. Primary biliary cholangitis (PBC): Consider in females with elevated ALP, positive AMA, and pruritus
14.Primary sclerosing cholangitis (PSC): Consider in patients with inflammatory bowel disease (IBD) and abnormal cholangiogram findings
15. Ischemic hepatitis: Consider in the setting of recent hypotension or cardiac arrest, typically presents with a rapid rise in AST/ALT
16. Biliary obstruction: Suspect if there is a history of gallstones or cholangiocarcinoma; check RUQ US or MRCP
TREATMENT
1. Alcoholic hepatitis: Treat with corticosteroids (prednisolone 40mg PO QD for 4 weeks) if Maddrey’s discriminant function >32, and supportive care including nutrition and abstinence from alcohol
2. Alcoholic cirrhosis: Manage with alcohol cessation, diuretics for ascites (e.g., spironolactone and furosemide), beta-blockers for variceal bleeding prevention (e.g., propranolol), and consider liver transplant evaluation in advanced cases
3. Alcoholic fatty liver disease: Recommend alcohol cessation, nutritional support (e.g., multivitamins, thiamine), and monitor liver enzymes; typically reversible with abstinence
4. Viral hepatitis A: Supportive care is the mainstay, including hydration and rest; avoid hepatotoxic medications like acetaminophen and alcohol
5. Viral hepatitis B (Acute): Supportive care, including rest and hydration; antiviral therapy is generally not indicated unless there is severe acute liver failure
6. Viral hepatitis B (Chronic): Antiviral therapy with tenofovir, entecavir, or pegylated interferon to suppress viral replication and prevent progression to cirrhosis and hepatocellular carcinoma; regular monitoring of liver function and HBV DNA levels
7. Viral hepatitis C: Antiviral therapy with direct-acting antivirals (DAAs) such as sofosbuvir, ledipasvir, or glecaprevir/pibrentasvir, aiming for sustained virologic response (SVR); monitor for liver function improvement and potential cirrhosis
8. Non-alcoholic fatty liver disease (NAFLD): Lifestyle modification with weight loss (targeting 7-10% of body weight), exercise, and control of metabolic syndrome (e.g., manage diabetes, hyperlipidemia); consider vitamin E or pioglitazone in biopsy-proven NASH
9. Autoimmune hepatitis: Initial treatment with corticosteroids (prednisone) to induce remission, followed by long-term azathioprine for maintenance therapy; regular monitoring of liver function and immunosuppressant levels
10. Hemochromatosis: Regular phlebotomy to maintain serum ferritin <50-100 ng/mL and manage iron overload complications; consider chelation therapy with deferoxamine if phlebotomy is contraindicated
11. Wilson’s disease: Lifelong treatment with chelation therapy (penicillamine or trientine) to remove excess copper, and zinc to block copper absorption; regular monitoring of liver function, copper levels, and adherence to a low-copper diet
12. Drug-induced liver injury (DILI): Immediate discontinuation of the offending drug, supportive care with hydration and nutrition, and consider N-acetylcysteine if acetaminophen is the cause; monitor liver function closely
13. Primary biliary cholangitis (PBC): First-line treatment with ursodeoxycholic acid (UDCA) 13-15mg/kg PO QD to slow disease progression, and consider obeticholic acid if inadequate response; monitor liver function and symptoms regularly
14. Primary sclerosing cholangitis (PSC): No definitive therapy; consider UDCA to improve liver biochemistry, monitor for cholangiocarcinoma, and consider liver transplant in advanced cases; manage symptoms and complications as they arise
15. Ischemic hepatitis: Supportive care with hemodynamic stabilization, addressing underlying cause of hypotension (e.g., fluids, vasopressors), and monitoring liver function as it typically recovers with improved perfusion
16. Biliary obstruction: Depending on the cause, may require endoscopic (ERCP) for stone removal or stenting, surgical intervention for tumors, or percutaneous drainage; manage any associated infections with antibiotics and supportive care
DIFFERENTIAL DIAGNOSIS (AS LIST)
1. Alcoholic hepatitis:
– Recent heavy alcohol intake
– Jaundice
– Tender hepatomegaly
– Elevated liver enzymes (AST:ALT ratio >2)
– Often with fever
– Leukocytosis
2. Alcoholic cirrhosis:
– Chronic alcohol use
– Signs of portal hypertension
– Ascites
– Varices
– Liver dysfunction
– Confirmed with imaging or biopsy showing nodular liver architecture
3. Alcoholic fatty liver disease:
– History of alcohol use
– Mild elevations in liver enzymes
– Imaging showing hepatic steatosis without signs of inflammation or fibrosis
4. Viral hepatitis A (HAV):
– Risk factors such as contaminated food or water
– Acute presentation
– Positive anti-HAV IgM
5. Viral hepatitis B (Acute):
– Recent exposure to HBV (e.g., sexual contact, IV drug use)
– Elevated liver enzymes
– Positive HBsAg and anti-HBc IgM
– Possible jaundice
6. Viral hepatitis B (Chronic):
– Persistent HBsAg >6 months
– Positive HBeAg or anti-HBe
– Elevated HBV DNA levels
– Risk of progression to cirrhosis or hepatocellular carcinoma
7. Viral hepatitis C (HCV):
– Risk factors such as IV drug use, blood transfusions before 1992
– Often asymptomatic or mild symptoms
– Positive anti-HCV and HCV RNA
– Risk of progression to chronic liver disease
8. Non-alcoholic fatty liver disease (NAFLD):
– Metabolic syndrome
– Obesity
– Diabetes
– Usually AST:ALT ratio <1
9. Autoimmune hepatitis:
– Positive autoimmune markers (ANA, ASMA, LKM1)
– Elevated IgG levels
– Absence of significant alcohol intake
10. Hemochromatosis:
– Family history
– Elevated ferritin and transferrin saturation
– Confirm with genetic testing
11. Wilson’s disease:
– Younger patients (<40 years)
– Neuropsychiatric symptoms
– Low ceruloplasmin
– Elevated urinary copper
12. Drug-induced liver injury (DILI):
– History of recent drug intake
– Common drugs: acetaminophen, statins, herbal supplements
13. Primary biliary cholangitis (PBC):
– Females
– Elevated ALP
– Positive AMA
– Pruritus
14. Primary sclerosing cholangitis (PSC):
– Inflammatory bowel disease (IBD)
– Abnormal cholangiogram findings
15. Ischemic hepatitis:
– Recent hypotension
– Cardiac arrest
– Rapid rise in AST/ALT
16. Biliary obstruction:
– History of gallstones
– History of cholangiocarcinoma
– Check RUQ US or MRCP
TREATMENT (AS LIST)
1. Alcoholic hepatitis:
– Corticosteroids (prednisolone 40mg PO QD for 4 weeks) if Maddrey’s discriminant function >32
– Supportive care including nutrition and abstinence from alcohol
2. Alcoholic cirrhosis:
– Alcohol cessation
– Diuretics for ascites (e.g., spironolactone and furosemide)
– Beta-blockers for variceal bleeding prevention (e.g., propranolol)
– Consider liver transplant evaluation in advanced cases
3. Alcoholic fatty liver disease:
– Alcohol cessation
– Nutritional support (e.g., multivitamins, thiamine)
– Monitor liver enzymes; typically reversible with abstinence
4. Viral hepatitis A:
– Supportive care including hydration and rest
– Avoid hepatotoxic medications like acetaminophen and alcohol
5. Viral hepatitis B (Acute):
– Supportive care including rest and hydration
– Antiviral therapy generally not indicated unless there is severe acute liver failure
6. Viral hepatitis B (Chronic):
– Antiviral therapy with tenofovir, entecavir, or pegylated interferon
– Regular monitoring of liver function and HBV DNA levels
7. Viral hepatitis C:
– Antiviral therapy with direct-acting antivirals (DAAs) such as sofosbuvir, ledipasvir, or glecaprevir/pibrentasvir
– Monitor for liver function improvement and potential cirrhosis
8. Non-alcoholic fatty liver disease (NAFLD):
– Lifestyle modification with weight loss (targeting 7-10% of body weight)
– Exercise and control of metabolic syndrome (e.g., manage diabetes, hyperlipidemia)
– Consider vitamin E or pioglitazone in biopsy-proven NASH
9. Autoimmune hepatitis:
– Initial treatment with corticosteroids (prednisone) to induce remission
– Long-term azathioprine for maintenance therapy
– Regular monitoring of liver function and immunosuppressant levels
10. Hemochromatosis:
– Regular phlebotomy to maintain serum ferritin <50-100 ng/mL
– Manage iron overload complications
– Consider chelation therapy with deferoxamine if phlebotomy is contraindicated
11. Wilson’s disease:
– Lifelong treatment with chelation therapy (penicillamine or trientine)
– Zinc to block copper absorption
– Regular monitoring of liver function, copper levels, and adherence to a low-copper diet
12. Drug-induced liver injury (DILI):
– Immediate discontinuation of the offending drug
– Supportive care with hydration and nutrition
– Consider N-acetylcysteine if acetaminophen is the cause
– Monitor liver function closely
13. Primary biliary cholangitis (PBC):
– First-line treatment with ursodeoxycholic acid (UDCA) 13-15mg/kg PO QD
– Consider obeticholic acid if inadequate response
– Monitor liver function and symptoms regularly
14. Primary sclerosing cholangitis (PSC):
– No definitive therapy; consider UDCA to improve liver biochemistry
– Monitor for cholangiocarcinoma
– Consider liver transplant in advanced cases
– Manage symptoms and complications as they arise
15. Ischemic hepatitis:
– Supportive care with hemodynamic stabilization
– Address underlying cause of hypotension (e.g., fluids, vasopressors)
– Monitor liver function as it typically recovers with improved perfusion
16. Biliary obstruction:
– Endoscopic (ERCP) for stone removal or stenting, if applicable
– Surgical intervention for tumors, if necessary
– Percutaneous drainage, if indicated
– Manage associated infections with antibiotics and supportive care